NCT04970836 The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
| NCT ID | NCT04970836 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Hepatitis B |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2021-08-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2021-08-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.
Eligibility Criteria
Inclusion Criteria: 1. The actual age at the time of admission was higher than 20 years old and birth year after 1987 2. Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period. 3. Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline 4. Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire 5. Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process 6. In good health Exclusion Criteria: 1. Those who were previously allergic to hepatitis B vaccine or its components (such as yeast) 2. Those who have been vaccinated against hepatitis B during childhood and adolescence 3. Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen
Contact & Investigator
CHYI-FENG JAN, MD, PhD
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT04970836 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 36 Years, studying Hepatitis B. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04970836 currently recruiting?
Yes, NCT04970836 is actively recruiting participants. Contact the research team at jcf036@gmail.com for enrollment information.
Where is the NCT04970836 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT04970836 clinical trial?
NCT04970836 is sponsored by National Taiwan University Hospital. The principal investigator is CHYI-FENG JAN, MD, PhD at National Taiwan University Hospital. The trial plans to enroll 240 participants.